Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Anadys Aims To Resume Hep C Trials By Year End Pending Toxicology Data

This article was originally published in Pharmaceutical Approvals Monthly

Executive Summary

Anadys Pharmaceuticals and partner Novartis plan to meet with FDA in the second half of the year to discuss the results of an ongoing preclinical toxicology study it hopes will lead FDA to lift a clinical hold on its oral hepatitis treatment ANA975, Anadys CEO Lawrence Fritz told Pharmaceutical Approvals Monthly Feb. 23

You may also be interested in...



Spectrum’s Iso-Vorin Could Clear FDA For Osteosarcoma By First Quarter

The Irvine, Calif., firm also plans sNDAs for a colorectal cancer claim and an oral formulation of the leucovorin relative.

Thelin's Third "Approvable" Letter Recommends Additional Clinical Trial

Encysive may be forced to make "significant reductions" to infrastructure and workforce, firm says June 15.

Sanofi Pentacel Revised Action Date Is Nov. 2

FDA extends the combination vaccine’s action date for the second time, this time requesting lab validation information relating to the pertussis component, but not directly related to Pentacel.

UsernamePublicRestriction

Register

LL016481

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel